Lapatinib for treatment of advanced or metastasized breast cancer: systematic review

Página do item simplificado
dc.contributor.authorRiera, Rachel [UNIFESP]
dc.contributor.authorSoarez, Patricia Coelho de [UNIFESP]
dc.contributor.authorPuga, Maria Eduarda dos Santos [UNIFESP]
dc.contributor.authorFerraz, Marcos Bosi [UNIFESP]
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2018-06-18T11:54:44Z
dc.date.available2018-06-18T11:54:44Z
dc.date.issued2009-09-03
dc.description.abstractCONTEXT AND OBJECTIVE: Around 16% to 20% of women with breast cancer have advanced, metastasized breast cancer. At this stage, the disease is treatable, but not curable. The objective here was to assess the effectiveness of lapatinib for treating patients with advanced or metastasized breast cancer.DESIGN AND SETTING: Systematic review of the literature, developed at Centro Paulista de Economia da Saude (CPES), Universidade Federal de Sao Paulo (Unifesp).METHOD: Systematic review with searches in virtual databases (PubMed, Lilacs [Literatura Latino-Americana e do Caribe em Ciencias da Saude], Cochrane Library, Scirus and Web of Science) and manual search.RESULTS: Only one clinical trial that met the selection criteria was found. This study showed that lapatinib in association with capecitabine reduced the risk of cancer progression by 51% (95% confidence interval, CI: 0.34-0.71; P < 0.001), compared with capecitabine alone, without any increase in severe adverse effects.CONCLUSION: The combination of lapatinib plus capecitabine was more effective than capecitabine alone for reducing the risk of cancer progression. Further randomized clinical trials need to be carried out with the aim of assessing the effectiveness of lapatinib as monotherapy or in association for first-line or second-line treatment of advanced breast cancer.en
dc.description.affiliationUniv Fed Sao Paulo, Ctr Paulista Econ Saude, BR-04023062 Sao Paulo, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Ctr Paulista Econ Saude, BR-04023062 Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipGlaxoSmithKline
dc.format.extent295-301
dc.identifierhttp://dx.doi.org/10.1590/S1516-31802009000500009
dc.identifier.citationSao Paulo Medical Journal. Sao Paulo: Associacao Paulista Medicina, v. 127, n. 5, p. 295-301, 2009.
dc.identifier.doi10.1590/S1516-31802009000500009
dc.identifier.fileS1516-31802009000500009.pdf
dc.identifier.issn1516-3180
dc.identifier.scieloS1516-31802009000500009
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/45547
dc.identifier.wosWOS:000274726900009
dc.language.isoeng
dc.publisherAssociacao Paulista Medicina
dc.relation.ispartofSao Paulo Medical Journal
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBreast neoplasmsen
dc.subjectReviewen
dc.subjectAntineoplastic agentsen
dc.subjectAntineoplastic protocolsen
dc.subjectReceptor, erbB-2en
dc.titleLapatinib for treatment of advanced or metastasized breast cancer: systematic reviewen
dc.title.alternativeLapatinib no tratamento do câncer de mama avançado ou metastático: revisão sistemáticapt
dc.typeinfo:eu-repo/semantics/article
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
S1516-31802009000500009.pdf
Tamanho:
129.28 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Coleções
EPM - Artigos